Advanced International Breast Cancer Course (AIBCC)

Aims

Mortality from breast cancer is declining in most countries thanks to effective screening programs, early diagnosis, molecular characterization of the different subtypes and biology-driven treatments. A multidisciplinary management of breast cancer patients is therefore the key to success and a breast multidisciplinary team should include - besides the “classic” clinical specialties - pathologists, molecular biologists and oncogeneticists. Furthermore, the availability of multiple diagnostic and therapeutic choices, the increasing costs of new technologies and drugs and the issue of sustainability represent a new challenge for socially-responsible clinicians. With this goal in mind, the Programme includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes.

Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.

This 15^th Breast Cancer Conference includes highly qualified international faculty, but will maintain its characteristics of a friendly forum where opinion leaders and attendees might exchange experiences and share the most exiting advances.

In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 15^th AIBCC will award the 9^th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year. We also welcome the presentation of posters from participants and the best poster will be awarded during the Award Ceremony.

The Conference is addressed to medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists who will have the opportunity to interact with breast cancer leaders and exchange experiences in a friendly atmosphere.

Addressed to

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

CME

Based on Italian regulations, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-265479): 11,9 CME points.

The credit certification is subject to:

• Professions/specializations should correspond to those which have been accredited for CME;
• 90% attendance to the meeting;
• Completion of the meeting evaluation form;
• Completion of the final questionnarie (at least 75% of correct answers).

We would like to remind you to participants that only 1/3 of CME credits acquired during the years 2017/2019 can come from a sponsorship.

Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

Thursday, October 10^th

8.30

Registration

9.15

 

Introduction to the Conference
Pierfranco Conte, Gabriel N. Hortobagyi

9.30

Lecture
Essential requirements for quality of care in breast cancer
Laura Biganzoli

SESSION I - PREVENTION AND SCREENING: FROM LIFE-STYLE TO MULTIGENE PANELS
Chairmen: Francesca Caumo, Stefania Zovato

10.00

Diet: myths and facts
Riccardo Caccialanza

10.20

Chemoprevention: how scientific evidence is applicable in daily practice
Claudine Isaacs

10.40

The wave of multigene panels
Marco Montagna

11.00

Personalized screening
Francesca Caumo

11.20

Q&A

11.30

Coffee break

 

SESSION II - LOCOREGIONAL TREATMENT
Chairmen: Jacek Jassem, Claudine Isaac

11.50

De-escalating surgery for breast cancer: the surgeon’s point of view
Viviana E. Galimberti

12.10

De-escalating surgery for breast cancer: the oncologist’s point of view
Gabriel N. Hortobagyi

12.30

Radiation therapy: updates
Philip Poortmans

12.50

Q&A

13.00

Lunch

14.00

Multidisciplinary Tumor Board 1 – Locoregional treatment
Chairmen: Viviana E. Galimberti

• Clinical case: Margins in DCIS
  Tania Saibene
• Clinical case: BLS before/after neoadjuvant therapy
  Sabrina Fontana Kahler Ribeiro
• Clinical case: Partial breast irradiation
  Emanuela Olmetto
• Concluding comments
  Viviana E. Galimberti

SESSION III – LIFE AFTER BREAST CANCER
Chairmen: Alessandra Andrisani, Stefania Migliuolo

15.30

Gynecologic consequences
Marco Gambacciani

15.50

Cognitive consequences
Matti Aapro

16.10

Social impact
Stefania Migliuolo

16.30

Pregnancy and fertility
Fedro Peccatori

16.50

Q&A

17.00

COFFEE WITH PROFESSORS - Career Development

• Clinical research in Breast Cancer: medical oncology
  Pierfranco Conte, Gabriel N. Hortobagyi
• Clinical research in Breast cancer: surgery and radiotherapy
  Viviana E. Galimberti, Philip Poortmans
• Translational research in breast cancer
  Mafalda Oliveira, Aleix Prat

18.00

Adjourn

Friday, October 11^th

8.00

Poster display

 

SESSION IV – PATHOLOGY, GENOMICS & MOLECULAR BIOLOGY
Chairmen: Enrico Orvieto, Aleix Prat

9.00

PDL1 test in breast cancer: which, when and why?
Giancarlo Pruneri

9.20

Tumor infiltrating lymphocytes in breast cancer: role in clinical practice
Roberto Salgado

9.40

Clinical impact of genomics for HER2+ and TNBC
Aleix Prat

10.00

Prognostic multigene assays for HR+ breast cancer: who are the patients to be tested?
Maria Vittoria Dieci

10.20

Q&A

10.40

Coffee break

 

SESSION V – SYSTEMIC TREATMENTS FOR EARLY BREAST CANCER
Chairmen: Stephen Johnston, Gabriel N. Hortobagyi

11.00

Neoadjuvant therapy: values and pitfalls
Valentina Guarneri

11.20

Enhancing chemotherapy for early TNBC: the debate around platinum and capecitabine
Hope Rugo

11.40

More or less chemotherapy? Role of anthracycline in the era of personalized medicine
Miguel Martin

12.00

Enhanced endocrine therapy: who needs extended endocrine therapy?
Stephen Johnston

12.20

Enhanced endocrine therapy for premenopausal patients: OFS plus what?
Sybille Lobil

12.40

Q&A

13.00

Lunch

14.00

Multidisciplinary Tumor Board 2 - Early breast cancer: challenging cases for pathologists and clinicians
Chairmen: Giancarlo Pruneri
Panelists: Gabriel N. Hortobagyi, Sybille Lobil, Miguel Martin, Enrico Orvieto, Aleix Prat

• Clinical case: “rare” HER2 ISH patterns (i.e. ratio >2.0 with HER2 copies <4; ratio<2.0 with HER2 copies 4-6)
  Vassilena Tsvetkova
• Clinical case: progression during NACT
  Luisa Carbongin
• Clinical case: HR+/HER2-ve (1 premenopause, 1 postmenopause) to discuss HT+/-OFS and Extended HT
  Giacomo Pelizzari
• Concluding comments
  Miguel Martin

 

SESSION VI – ADVANCED BREAST CANCER
Chairmen: Miguel Martin, Hope Rugo

New therapeutic algorithms

15.30

HR+ disease: what after failure of CDK4/6 inhibitors?
Stephen Johnston

15.50

HER2+ disease
Sandra Swain

16.10

Biopsy of metastases and ctDNA to guide treatment
Gabriel N. Hortobagyi

16.30

Q&A

16.45

Updates in immunotherapy for breast cancer
Peter Schmid

17.00

Adjourn

18.00

Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2019 and best poster award

18.15

Lecture of the Awardee

18.45

Cocktail

19.30

Adjourn

Saturday, October 12^th

 

SESSION VII – ACTIONABLE PATHWAYS AND NEW DRUGS
Chairmen: Pierfranco Conte, Sybille Loibl

9.00

Multidisciplinary Tumor Board 3 – Management of Advanced Breast Cancer
Chairmen: Sandra Swain
Panelists: Jacek Jassem, Stephen Johnston, Philip Poortmans, Hoper Rugo

• Clinical case: CDK4/6: Management of toxicity
  Carlo Alberto Giorgi
• Clinical case: Brain disease or leptomeningeal disease
  Gaia Griguolo
• Clinical case: Discordant phenotype
  Federica Miglietta
• Clinical case: Visceral oligometastatic disease
  Giuseppe Buono
• Concluding comments
  Sandra Swain

11.30

Coffee break

11.50

New promising drugs in development: special focus on AKT/PI3K inhibitors and PARP inhibitors
Giuseppe Curigliano

12.10

NGS in metastatic breast cancer: promises and pitfalls
Mafalda Oliveira

10.30

Q&A

13.00

Adjourn and final evaluation questionnaire